Citi maintains a 'Hold' rating on Progenics Pharmaceuticals Inc (Nasdaq: PGNX), but increases price target from $13 to $17.

This article: 124 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE